Associated Papers
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
34621706 (PubMed )
Supplement: tcp-29-135-s001.xls › tcp-29-135-s001
ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
Chen S et al.
Pharmacogenetics and Genomics, 2015
The Affymetrix DMET Plus platform reveals unique distribution of ADME-related variants in ethnic Arabs.
Wakil SM et al.
Disease Markers, 2015
25802476 (PubMed )
Supplement: 542543.f1.xlsx › DMET_Suppl_data
Pharmacogenetics of antiretroviral therapy.
Barreiro P et al.
Expert Opinion on Drug Metabolism & Toxicology, 2014
Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
Wang J et al.
Plos One, 2014
25372392 (PubMed )
Supplement: pone.0111694.s006.pdf
The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.
Yamada A et al.
Pharmacogenetics and Genomics, 2011
Analysis of pharmacogenetic traits in two distinct South African populations.
Ikediobi O et al.
Human Genomics, 2011
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
Fujita K et al.
Biological & Pharmaceutical Bulletin, 2008
Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients.
Naesens M et al.
Transplantation, 2006
Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
Bosch TM et al.
Molecular Diagnosis & Therapy, 2006
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
Select a paper to view details